Osteosarcoma clinical trials

Explore recruiting osteosarcoma clinical trials.

Recruiting osteosarcoma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Osteosarcoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 2 Pilot Study to Evaluate the Safety and the Anti-Tumour Activity of the Myc Inhibitor OMO-103 Administered Intravenously in Patients with Advanced High-Grade Osteosarcoma

Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

Fight Osteosarcoma Through European Research evolving study platform from diagnosis to relapse (FOSTER evolving study platform)

Sweden, Poland, Denmark, Finland, Netherlands, Italy +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

SARCOME 13 / OS2016 - A Multicentre, Randomised, Open-label, Phase 2 trial of mifamurtide combined with post-operative chemotherapy for newly diagnosed high risk osteosarcoma patients (metastatic osteosarcoma at diagnosis or localised disease with poor histological response)

France

Therapeutic exploratory (Phase II) EU CTIS Study details

Metformin as maintenance therapy in bone sarcomas at high risk of relapse

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

A phase II, randomized, open-label study to assess the efficacy, safety, and pharmacokinetics (PK) of maintenance cabozantinib (XL184) plus best supportive care (BSC) versus BSC in children, adolescents and young adults (AYA) with unresectable residual osteosarcoma either at diagnosis or at first relapse after standard treatment.

Poland, France, Netherlands, Sweden, Italy, Spain +5 more

Therapeutic exploratory (Phase II) EU CTIS Study details

SARCOME 09_Intergroup Study (SFCE/GSF-GETO) OS2006 - Zoledronate Osteosarcoma Treatment Protocol for osteosarcoma of the child, adolescent and adult including: - A randomized trial - And biological studies.

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

Osteosarcoma trials by city

Osteosarcoma in Toronto Osteosarcoma in Vancouver Osteosarcoma in Montreal Osteosarcoma in Calgary Osteosarcoma in Edmonton Osteosarcoma in Ottawa Osteosarcoma in Winnipeg Osteosarcoma in Quebec City Osteosarcoma in Hamilton Osteosarcoma in Kitchener Osteosarcoma in London Osteosarcoma in Halifax Osteosarcoma in New York Osteosarcoma in Los Angeles Osteosarcoma in Chicago Osteosarcoma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease